Looking to take advantage of 'silenced' enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

Max Gelman

Senior Editor

Gene therapy has made big strides over the years, from the first generation AAV-based therapies to the CRISPR/Cas9 technology that has now taken the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Looking to take advantage of 'silenced' enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Look­ing to take ad­van­tage of 'si­lenced' en­zymes, Sali­o­Gen emerges from stealth with eyes set on gene ther­a­py 3.0

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Looking to take advantage of 'silenced' enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial